Age-related Macular Degeneration Treatment Market Size, Share, and Trends 2024 to 2033

Age-related Macular Degeneration Treatment Market Size and Growth 2024 to 2033

The global age-related macular degeneration treatment market size was USD 11.28 billion in 2023, calculated at USD 12.06 billion in 2024, and is expected to reach around USD 22.05 billion by 2033, expanding at a CAGR of 6.93% from 2024 to 2033. The rising developments in healthcare systems across the world is driving the growth of the age-related macular degeneration treatment market.

Age-related Macular Degeneration Treatment Market Key Takeaways

• The North America age-related macular degeneration treatment market size reached USD 5.75 billion in 2023 and is expected to expand around USD 11.36 billion by 2033, at a CAGR of 7.04% from 2024 to 2033.
• North America led the market with the largest revenue share of 51% in 2023.
• Asia-Pacific is expected to experience the fastest rate of growth during the forecast period.
• By product, the eylea segment has held a major revenue share of 52% in 2023.
• By product, the Beovu segment is expected to grow with the highest CAGR during the forecast period.
• By disease type, the wet AMD segment has contributed more than 98% of revenue share in 2023.
• By disease type, the dry AMD segment is expected to be the fastest-growing segment during the forecast period.
• By distribution channel, the hospital pharmacy segment has held a biggest revenue share of 52% in 2023.
• By distribution channel, the specialty pharmacy segment is estimated to witness the fastest growth during the forecast period.

U.S. Age-related Macular Degeneration Treatment Market Size and Growth 2024 to 2033

The U.S. age-related macular degeneration treatment market size was valued at USD 4.03 billion in 2023 and is predicted to be worth around USD 8.01 billion by 2033 with a CAGR of 7.11% from 2024 to 2033.

North America holds the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of this region is mainly driven by the rising technological developments in the healthcare industry. Also, the increasing cases of age-related macular degeneration (AMD) diseases in countries such as the U.S. and Canada have increased the demand for treatment of this eye disorder, thereby driving market growth. Moreover, the announcement of new government initiatives for developing treatment methodologies for age-related macular degeneration diseases has also boosted the growth of the age-related macular degeneration (AMD) treatment market. Furthermore, market players such as Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR LLC, Coherus, and others drive the growth of the age-related macular degeneration treatment market. 

• According to the Centers for Disease Control and Prevention (CDC), around 20 million Americans aged 40 and above suffered from age-related macular degeneration disease in the U.S. in 2023-24.
• For instance, in May 2022, the National Eye Health Institute of the U.S.A. announced an NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This initiative was launched to determine the iPSC-derived cell lines that may be used to find the underlying pathophysiology of AMD.
• For instance, in October 2022, Coherus announced that the U.S. Food and Drug Administration (FDA) had approved CIMERLI for treating patients suffering from neovascular (wet) age-related macular degeneration (AMD).

Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of this region is mainly driven by the scientific advancements in the healthcare sector in countries such as India, Israel, China, Japan, and some others. Also, the growing interest from the public and private sectors for development & research related to the treatment of age-related macular degeneration disease has also boosted the age-related macular degeneration treatment market growth. Additionally, the rising prevalence of age-related macular degeneration diseases (AMDs) across Asia increases the demand for treatment of this disease, which in turn drives the market growth. Moreover, rising government investment in countries such as India, China, and Japan to develop the eye care sector has boosted market growth. Furthermore, the presence of local market players in eye medications, such as Tarsier Pharma, Astellas Pharma, Chugai, and some others, has driven the growth of the age-related macular degeneration treatment market.

• For instance, in March 2024, the government of Karnataka’s Health and Family Welfare Department in India partnered with the Centre for Cellular and Molecular Platforms (C-CAMP). This partnership is done to launch an initiative named Asha Kirana to strengthen the eye care sector in Karnataka, India.
• In May 2022, Chugai launched Vabysmo Intravitreal Injection. This injection is effective for the treatment of age-related macular degeneration related to diabetic macular edema and subfoveal choroidal neovascularization. 
• In March 2023, the government of Andhra Pradesh in India collaborated with Apollo Telehealth. This collaboration was initiated according to the Andhra Pradesh government’s Mukhyamantri e-Eye Kendram Initiative. This collaboration aims to provide eye care services to more than 2.5 million people across 115 tele-eye care centers in Andhra Pradesh.

Market Overview

The age-related macular degeneration treatment market has grown rapidly with the advancements in modern science and technologies. Age-related macular degeneration occurs among patients due to several factors, such as unhealthy diet patterns and the growing adoption of a sedentary lifestyle. Also, excessive use of smartphones, tablets, televisions, and other electronic gadgets due to prolonged screen time leads to eye damage among people. The growing adoption of computers and laptops among working professionals is another factor that causes macular degeneration. Also, anti-VGEF injections are mainly administered to treat a macular degeneration patient above 50.

This industry is highly supported by a rise in eye clinics and ophthalmic centers worldwide. The governments of several countries have started collaborating with telehealth providers for the treatment of macular degeneration, which acts as a driving factor for industrial growth. This industry is also expected to grow. The integration of advanced eye testing systems in hospitals and ophthalmologic centers has also contributed to the market growth.

The developments and research of new medicines and therapies effective against macular degeneration will likely positively support age-related macular degeneration treatment market growth. The therapies and injections for treating this disorder can be purchased from hospital pharmacies, specialty pharmacies, and online platforms.

• In March 2024, Roche launched Vabysmo in India. Vabysmo (sarilumab) is an injection that is effective for treating patients suffering from wet age-related macular degeneration and diabetic macular edema.
• In November 2023, the UK government announced an investment of around 2 billion euros to strengthen the country’s position in genetic engineering. This investment aims to develop new medicines and therapies, improve crops, and produce biofuels.

Age-related Macular Degeneration Treatment Market Growth Factors

• The ongoing development in the healthcare industry has boosted the market growth.
• Technological advancements in medicine industries are expected to drive the growth of the age-related macular degeneration treatment market.
• The increasing government initiatives to strengthen the healthcare sector have driven the market growth.
• The rising investments from public and private sector entities for developing the age-related macular degeneration treatment industries also boost market growth.
• The increasing prevalence of eye disorders across the world is boosting the market growth.
• The rising trend of medical tourism across the world has boosted the market growth.
• The growing number of government and private hospitals around the globe also propels age-related macular degeneration treatment market growth.

Age-related Macular Degeneration Treatment Market Scope

Age-related Macular Degeneration Treatment Market Dynamics

Driver

Rising cases of obesity across the world

The cases of obesity have increased rapidly in recent times due to factors such as diet, environmental factors, lack of exercise, and genetics. According to the World Obesity Atlas 2024, around 79% of adults will be suffering from overweight and obesity in low and middle-income countries in 2035. It is also estimated that the number of adults with obesity will increase from 0.81 billion in 2020 to 1.53 billion in 2035. Thus, with the growing cases of obesity, the associated macular degeneration problems also increase, increasing the demand for age-related macular degeneration treatment, thereby driving the age-related macular degeneration treatment market growth.

Restraint

Availability of biosimilars and off-label drugs

The availability of several biosimilars that are found effective for the treatment of macular degeneration disorder has allowed people to take up these medicines due to their affordability. This, in turn, restrains the market growth to some extent. Moreover, easy accessibility of off-label drugs in local medical shops at lower prices is also expected to restrain the growth of the age-related macular degeneration treatment market during the forecast period.

Opportunity

Genetic therapies to shape the future of the market

There are several medications available in the market for the treatment of macular degeneration problems around the world. Recently, scientific advancements in genetic engineering have also enabled biotechnology companies to produce gene therapies for treating age-related macular degeneration disorders. Thus, growing developments in gene therapies for eye treatment are expected to create ample growth opportunities for the age-related macular degeneration treatment market players in the future.

• For instance, in April 2024, ViGeneron GmbH started the clinical trial of gene therapy for eye treatment. This gene therapy uses a gene delivery technology known as vgAAV, and the gene used is CNGA1, which helps in phototransduction.

Product Type Insights

The eyelea segment held the largest share in 2023, and it is expected to maintain its dominance throughout the forecast period. The growth of this segment is driven by the growing number of patients suffering from wet age-related macular degeneration (AMD) disease. Also, rising approval of aflibercept by various organizations for treating wet age-related macular degeneration (AMD) disorder has driven market growth.

The Beovu segment is expected to be the fastest-growing segment during the forecast period. The growth of this segment can be attributed to rising developments in the pharmaceutical sector. Also, the growing application of beloved for treating patients suffering from chronic eye disorders such as AMD and DME drives the growth of the wet age-related macular degeneration treatment market. The European Union recognized Beovu as the most effective medication for treating adults with eye problems.

Disease Type Insights

The wet AMD segment held the largest market share in 2023. The growth of this segment is generally driven by a rising patient pool along with improved diagnosis and drug treatment for treating this disease. Also, the growing geriatric population coupled with rising developments in therapeutics for treating wet AMD has driven the growth of the age-related macular degeneration treatment market. Moreover, healthcare care companies are constantly engaged in research & development of wet AMD medications and adopting strategies such as approvals, product launches, and some others, which, in turn, drive market growth.

• For instance, in April 2023, Eyevensys announced the launch of EYS809. The EYS809 is a dual plasmid gene therapy that is effective for treating patients suffering from wet age-related macular degeneration (AMD).

The dry AMD segment is expected to be the fastest-growing segment during the forecast period. The growth of this segment is mainly driven by the rising number of clinical trials for the treatment of dry AMD. Moreover, the development of high-grade anti-VGEFs for the treatment of dry AMD has driven the growth of the age-related macular degeneration treatment market. Also, the growing number of ophthalmic centers that are engaged in treating dry AMDs is boosting market growth.

• For instance, in November 2023, Inflammasome Therapeutics announced the first clinical trial of Kamuvudines. Kamuvudines is an inflammasome inhibitor drug that is effective for the treatment of dry AMD.

Distribution Channel Insights

The hospital pharmacy segment dominated the market in 2023 and is expected to continue its dominance during the forecast period. The growth of this segment is generally driven by the rise in the number of public hospitals across the world. Also, patients suffering from Dry AMD and Wet AMD have increased globally, which increases the demand for macular degeneration treatment in hospitals, thereby driving the market growth. Moreover, the availability of quality doctors in hospitals, along with the construction of hospitals with well-equipped pharmacies having huge stocks of medicines, has also driven the growth of the age-related macular degeneration treatment market.

The specialty pharmacy segment is estimated to grow with the highest CAGR during the forecast period. The growth of this segment is generally driven by the growing demand for macular degeneration treatment therapies among people across the world. Also, these pharmacies keep huge stocks of costly medications and allow insurance reimbursements for buying various medicines, thereby driving market growth. Moreover, specialty pharmacies provide home deliveries of medicines that further drive the growth of the age-related macular degeneration treatment market.

Age-related Macular Degeneration Treatment Market Companies

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Amgen Inc.
• Bayer AG
• Biogen
• Samsung Bioepis
• Abbvie, Inc

Recent Developments

• In October 2023, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo for the treatment of Retinal Vein Occlusion (RVO), neovascular or wet age-related macular degeneration, and diabetic macular edema.
• In August 2023, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved EYLEA HD injection for treating patients suffering from wet age-related macular degeneration.
• In August 2023, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) had approved IZERVAY injection for geographic atrophy (GA) and age-related macular degeneration (AMD) disease.
• In February 2023, Apellis announced that the U.S. Food and Drug Administration (FDA) had approved SYFOVRE injection for the treatment of geographic atrophy (GA) and age-related macular degeneration (AMD) disease.

Segments Covered in the Report

By Product

• Eylea
• Lucentis
• Beovu
• Others

By Disease Type

• Dry AMD
• Wet AMD

By Distribution Channel

• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa